The global alopecia market size is expected to reach USD 16.02 billion by 2030, registering a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The approval of JAK inhibitors and tyrosine kinase inhibitors along with the rising target disease prevalence is expected to drive market growth.
The prevalence of alopecia areata (AA) and alopecia totalis is increasing globally. It is one of the most commonly encountered problems in clinics in the U.S. As per a research article published in March 2023, in the U.S. and UK, AA accounted for 0.6% to 2% of the new cases encountered in dermatology clinics. In hospital-based studies performed worldwide the incidence of AA is estimated to range between 0.57% to 3.8%.
The approval of new targeted pharmaceutical treatments is a key factor driving the alopecia market growth. For instance, in June 2022, the U.S. FDA approved Lilly’s Olumiant oral tablets for the treatment of severe alopecia in adult patients and is the first systemic treatment approved. Another key drug that is anticipated to be approved in 2023 is Pfizer’s Ritlecitinib. It is a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinases.
Another key factor driving the industry’s growth is the increasing awareness regarding alopecia and thereby increasing treatment rates worldwide. The increase in the level of consciousness regarding physical appearance is one of the major reasons for the rising number of people seeking treatment. Additionally, rising investments in R&D and funding are also fueling market growth.
The limited availability of targeted drugs that treat the underlying condition is one key challenge for the market. While new products with targeted mechanisms of action are being approved the high cost of these drugs in comparison to the already approved products is one of the major hindrances in their widespread adoption.
Request a free sample copy or view report summary: Alopecia Market Report
The alopecia universalis segment is expected to witness the fastest growth from 2024 to 2030, owing to the impending approval of pipeline products, such as Pfizer’s Ritlecitinib which is in the pre-registration phase, and Bioniz Therapeutics’s BNZ-1 which is in phase 2 clinical trials
North America dominated the market in 2023, mainly due to the high consumer awareness, technological advancements, high target disease population, and high healthcare spending
Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be majorly attributed to the rising target disease population and rising treatment rate for the disease.
Grand View Research has segmented the global alopecia market based on disease type, treatment, gender, sales channel, end-use, region:
Alopecia Disease Type Outlook (Revenue, USD Million; 2018 - 2030)
Alopecia Areata
Male
Female
Cicatricial Alopecia
Male
Female
Traction Alopecia
Male
Female
Alopecia Totalis
Male
Female
Alopecia Universalis
Male
Female
Androgenetic Alopecia
Male
Female
Others
Male
Female
Alopecia Treatment Outlook (Revenue, USD Billion, 2018 - 2030)
Pharmaceuticals
Topical
OTC
Minoxidil
Others
Prescription
Betamethasone Dipropionate
Fluocinolone Acetonide
Finasteride
Minoxidil
Oral
OTC
Prescription
Minoxidil
Finasteride
Corticosteroids
Others (JAK inhibitors and others)
PRP
Devices
Laser Cap
Laser Comb
Laser Helmet
Alopecia Gender Outlook (Revenue, USD Billion, 2018 - 2030)
Male
Female
Alopecia Sales Channel Outlook (Revenue, USD Billion, 2018 - 2030)
Prescriptions
OTC
Alopecia End Use Outlook (Revenue, USD Billion, 2018 - 2030)
Homecare Settings
Dermatology Clinics
Alopecia Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Denmark
Norway
Sweden
Asia Pacific
China
Japan
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
UAE
Saudi Arabia
Kuwait
List of Key Players of Alopecia Market
Janssen Global Services Inc.
Cipla Limited
Merck & Co., Inc.
GlaxoSmithKline plc
Sun Pharmaceuticals Industries Ltd
Dr. Reddy’s Laboratories Ltd
Aurobindo Pharma
Viatris Inc.
Pfizer, Inc.
Lilly
Lexington Intl., LLC (Devices)
Freedom Laser Therapy (iRestore ID-520 helmet)
Curallux, LLC.
Apira Science Inc. (iGROW Laser)
Revian Inc.
Theradome
Lutronic
"The quality of research they have done for us has been excellent..."